Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
Plus
21
Ṁ9232026
33%
chance
1D
1W
1M
ALL
a black box warning by FDA or withdrawal from market for adverse events by 12/31/2025 resolves this market YES
This question is managed and resolved by Manifold.
Get
1,000
and3.00
Sort by:
made a related market and added a large subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl?r=QW5keU1hcnRpbg
More reports of gastroparesis https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html
Related questions
Related questions
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
23% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
12% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will aducanumab be withdrawn by the FDA by 2025?
47% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
64% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance